| Literature DB >> 33036279 |
Chia-Jung Lee1,2,3, Chun-Wei Huang2, Lih-Geeng Chen4, Ching-Chiung Wang1,2,3,5.
Abstract
Acne is a common skin condition observed in adolescents. Nutmeg (Myristica fragrans Houtt) (MF) is a well-known traditional Chinese medicine; its major toxic components, safrole and myristicin, are rich in essential oils. Essential oils of MF (MFO) were extracted by hydrodistillation; the residue was extracted using 50% methanol (MFE-M). The minimum inhibitory concentration (MIC) of MFE-M against Cutibacterium acnes and Staphylococcus aureus was 0.64 mg. Four compounds were obtained from MFE-M: myristicin (1), (+)-erythro-Δ8'-7S,8R- dihydroxy-3,3,5'-trimethoxy-8-O-4'-neolignan (2), (+)-erythro-Δ8'-7-hydroxy-3,4,3',5'-tetramethoxy 8-O-4-neolignan (3), and erythro-Δ8'-7-acetoxy-3,4,3',5'-tetramethoxy-8-O-4'-neolignan (4). Compound 2 exerted the strongest antimicrobial activity, with MICs of 6.25 and 3.12 μg/mL against C. acnes and S. aureus, respectively. Moreover, 2 inhibited NO, PGE2, iNOS, and COX-2 levels in RAW 264.7 cells induced by LPS or heat-killed C. acnes; NO production at 50% inhibitory concentrations (IC50) was 11.07 and 11.53 μg/mL, respectively. Myristicin and safrole content was higher in MFO than in MFE-M. MFO and MFE-M caused no skin irritation after a single topical application in Wistar rats. MFE-M, with low safrole and myristicin content, did not cause skin irritation and exhibited an anti-acne effect; moreover, 2 was identified as the active substance. Therefore, MFE-M could be employed to develop anti-acne compounds for use in cosmetics.Entities:
Keywords: Cutibacterium acnes; Myristica fragrans Houtt; Staphylococcus aureus; anti-acne effect; anti-inflammatory effect; skin irritation
Mesh:
Substances:
Year: 2020 PMID: 33036279 PMCID: PMC7582466 DOI: 10.3390/molecules25194563
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Isolation flowchart of the degreasing of Myristica fragrans using antibacterial bioassay-guided fractionation. The structures of myristicin (1), (+)-erythro-Δ8′-7S,8R- dihydroxy-3,3′,5′-trimethoxy-8-O-4′-neolignan (2), (+)-erythro-Δ8′-7-hydroxy-3,4,3′,5′-tetramethoxy- 8-O-4′-neolignan (3), and erythro-Δ8′-7-acetoxy-3,4,3′,5′-tetramethoxy-8-O-4′-neolignan (4) are shown. F1 to F10 indicated different eluted fractions.
Antibacterial activity of myristicin and three neolignans.
| Microorganisms | MIC µg/mL | |||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
|
| >100 | 6.25 | 100 | 25 |
|
| 12.5 | 3.12 | 6.25 | 12.5 |
Figure 2Effects of M. fragrans on LPS (500 ng/mL)-stimulated RAW 264.7 cells after 24 h of treatment. NO inhibition percentage of MFE-M, MFE-H, and MFE-E (A). PGE2 inhibition percentage of MFE-E at various concentrations (6.25–25 µg/mL) (B). * p < 0.01 compared with Control; B: Blank (without LPS induction), C: Control (LPS induction without MFE-E treatment).
Figure 3Anti-inflammatory effects of (+)-Erythro-(7S,8R)-Δ8′,3,3′,5′-trimethoxy-8-O-4′-neolignan (2) (A) against HKC-induced PGE2 inhibitory effects on nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 at 8 h (B) and 24 h (C). * p < 0.01 compared with Control; B: Blank (without HKC induction), C: Control (HKC induction without 2 treatment).
Figure 4HPLC chromatograms displaying the components of MFO (A) and MFE-M (B).